I would make two observations.
First, I would note with caution the Korean experience. Korea was exactly at this point 10 to 15 years ago. It drew exactly the same lessons you have from this and spent a huge amount of money on building a vaccine industry that has not delivered this time around. Having the vaccine capacity there is, at most, an unnecessary condition for success.
The alternative I would put to you is much smarter sourcing. It has been said by one CEO of a pharma company that the reason they wanted to source from Switzerland is that Switzerland only has seven million people and its production capacity was into the tens of millions of doses. Even if the Swiss government needed vaccines for every single Swiss person, there would still be a huge amount that would be left—